Research
Hormonal
Faecal Microbiota Transplantation (FMT) from lean donors to individuals with metabolic syndrome can significantly increase insulin sensitivity and butyrate production, establishing a causal link between microbiota composition and host glucose homeostasis.
FMT from lean donors is a potent intervention for improving insulin sensitivity in metabolic syndrome, primarily by boosting butyrate-producing bacteria. It is currently a medical procedure, not a consumer product.
GoodSupportsHIGH confidence
FMT from lean donors to individuals with metabolic syndrome significantly increased their insulin sensitivity. The transplant produced an increase in faecal butyrate concentrations, microbial diversity and the relative abundance of bacteria related to the butyrate-producing Roseburia intestinalis.
Why this rating
Cited as a causal relationship in human studies, though sample sizes in cited studies may be small.
Source
The gut microbiota and host health: a new clinical frontier
Julian R. Marchesi et al. · Gut · 2015
DOI 10.1136/gutjnl-2015-309990
narrative_reviewCited 2,301×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut dysbiosis, characterized by reduced bacterial diversity and butyrate production, contributes to the pathogenesis of liver diseases (NAFLD, NASH, Alcoholic Liver Disease, PSC) through the translocation of bacterial products (endotoxins) to the liver, triggering inflammation.Good
- Dietary modulation of the gut microbiota, specifically through the intake of prebiotics, probiotics, and polyphenols, can alter microbial composition and metabolic activity to confer health benefits, although human clinical efficacy remains ambiguous compared to animal models.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →